Praxis Precision Medicines, Inc. PRAX

Praxis Precision Medicines just posted a $92.6 million net loss for the quarter ended 31 March 2026, turning the first three months of 2026 into a financial haemorrhage that makes a slow leak look heroic. Revenue remained at zero-because, at this stage, selling pills is still a future tense. Operating losses reached $105.9 million while cash and equivalents sat at $536.3 million, which is enough to keep the lights on but not enough to silence the sceptics who note the company has yet to ship a product that anyone can buy.

The company’s pipeline centres on vormatrigine, a small-molecule sodium-channel blocker designed to curb focal onset seizures. On 1 June 2026 Praxis issued a press release trumpeting the Phase 2/3 POWER1 study results, but the release is filed with the SEC as Exhibit 99.2 rather than appearing in a peer-reviewed journal, leaving investors to parse topline data without the safety net of peer review or a published dossier. The company’s own investor-relations site hosts polished slide decks and forward-looking statements, while the latest 10-Q quietly reminds readers that the top line is still a blank page.

Numbers from the SEC filings tell the story in black and white. For the quarter ended 31 March 2026, Praxis reported net income attributable to parent of minus $92.6 million, operating loss of minus $105.9 million, and diluted loss per share of minus $3.20 on 28.9 million diluted shares. Cash and cash equivalents stood at $536.3 million while liabilities totalled $50.2 million, giving the balance sheet an air of solvency that evaporates the moment the revenue column refuses to budge. Research and development expense clocked in at $78.0 million, so the burn rate is not just real-it’s turbo-charged. Operating cash outflow was $86.2 million, while capital expenditure was a mere $62,000, which suggests the company is renting rather than building. Assets totalled $1.46 billion and shareholders’ equity attributable to parent amounted to $1.41 billion, a pair of figures that look healthier than they feel.

SEC filings are the only source of truth here, and they arrive with admirable frequency. A cluster of six Form 4 insider-trading disclosures on 12 June 2026 suggests executives are repositioning options fast enough to make a day-trader jealous, while the SEC’s JSON submissions feed for Praxis shows the filing machine is still humming. The company’s EDGAR 8-K dated 1 June 2026 and 7 May 2026 respectively announce the POWER1 data release and Q1 results, but neither document contains audited revenue or a commercial approval. The SEC’s companyfacts JSON and the filing index confirm the red ink and the cash pile, but they cannot conjure sales from a pipeline that has not yet reached a pharmacy shelf.

The stock screen will show a ticker, but the reality is a pre-revenue biotech that files fast and spends faster. If you want to see the ticker in motion, the SEC EDGAR index for Praxis Precision Medicines is the only place to start; the TradingView chart will show you the price, but it cannot tell you when-or whether-the product will ever show up (source: SEC EDGAR CIK 1689548 index, https://www.sec.gov/edgar/browse/?CIK=1689548).